Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
The (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial) CABANA Trial has the overall goal of establishing the appropriate roles for medical and ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy with either rate control or rhythm control drugs for reducing total mortality in patients with untreated or incompletely treated AF.
- device : Left atrial ablation
- drug : Rate or Rhythm Control Therapy
Ages Eligible For Study:
- Have the capacity to understand and sign an informed consent form - Be ?18 years of age. - Have documented AF episodes ?1 hour in duration; with ?2 episodes over 4 months with electrocardiographic documentation of 1 episode or at least 1 episode of AF lasting more than 1 week - Warrant active therapy beyond simple ongoing observation - Be eligible for both catheter ablation and ?2 sequential rhythm control and/or ?3 rate control drugs. - Be ?65 yrs of age, or <65 yrs with one or more of the following risk factors for stroke: Hypertension, Diabetes, Congestive heart failure, Prior stroke or TIA, LA size ?5.0 cm (or volume index ?40 cc/m2), or EF ?35. Subjects <65 yrs of age whose only risk factor is hypertension must have a second risk factor or LV hypertrophy to qualify.